Gregg CapponPfizer Inc Drug Safety R&D关注立即认领分享关注立即认领分享基本信息浏览量:0职业迁徙个人简介暂无内容研究兴趣论文共 2 篇作者统计合作学者相似作者按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选时间引用量主题期刊级别合作者合作机构CO-ADMINISTRATION OF THE ACC INHIBITOR PF-05221304 AND THE DGAT2 INHIBITOR PF-06865571 IS SAFE AND WELL TOLERATED IN SHORT-TERM STUDIES IN NON-HUMAN PRIMATES AND HUMANS WITH NO CLINICALLY MEANINGFUL PHARMACOKINETIC INTERACTIONRoberto Calle,Gregg Cappon,Veena Somayaji,William Esler,Arthur BergmanHEPATOLOGY(2019)引用1浏览0引用10DE NOVO LIPOGENESIS IS CRITICAL FOR PLATELET PRODUCTION; THE LIVER DIRECTED ACC INHIBITOR PF-05221304 FOR THE TREATMENT OF NASH SHOWS IMPROVED PLATELET SAFETY PROFILE OVER SYSTEMIC ACC INHIBITION Jr. Kelly Kenneth,William J. Reagan,Gabriele Sonnenberg,Arthur Bergman,Michelle Clasquin,Paul Amor,Santos Carvajal-Gonzalez,Norimitsu Shirai,Marc Hellerstein,Kelvin Li,Nicholas Vera,Trenton R. Ross,HEPATOLOGY(2019)引用2浏览0引用20作者统计合作学者合作机构D-Core合作者学生导师暂无相似学者,你可以通过学者研究领域进行搜索筛选数据免责声明页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn